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Summary
Background Plasmodium falciparum and Plasmodium vivax infections are important causes of adverse pregnancy 
outcomes in the Asia-Pacific region. We hypothesised that monthly intermittent preventive treatment (IPT) or 
intermittent screening and treatment (IST) with dihydroartemisinin–piperaquine is more effective in reducing 
malaria in pregnancy than the existing single screening and treatment (SST) strategy, which is used to screen women 
for malaria infections at the first antenatal visit followed by passive case detection, with management of febrile cases.
Methods We did an open-label, three-arm, cluster-randomised, superiority trial in Sumba (low malaria transmission 
site) and Papua (moderate malaria transmission site), Indonesia. Eligible participants were 16–30 weeks pregnant. 
Clusters (antenatal clinics with at least ten new pregnancies per year matched by location, size, and malaria risk) were 
randomly assigned (1:1:1) via computer-generated lists to IPT, IST, or SST clusters. In IPT clusters, participants 
received the fixed-dose combination of dihydroartemisinin-piperaquine (4 and 18 mg/kg per day). In IST clusters, 
participants were screened with malaria rapid diagnostic tests once a month, whereas, in SST clusters, they were 
screened at enrolment only. In all groups, participants with fever were tested for malaria. Any participant who tested 
positive received dihydroartemisinin–piperaquine regardless of symptoms. The primary outcome was malaria 
infection in the mother at delivery. Laboratory staff were unaware of group allocation. Analyses included all randomly 
assigned participants contributing outcome data and were adjusted for clustering at the clinic level. This trial is 
complete and is registered with ISRCTN, number 34010937.
Findings Between May 16, 2013, and April 21, 2016, 78 clusters (57 in Sumba and 21 in Papua) were randomly assigned 
to SST, IPT, or IST clusters (26 clusters each). Of 3553 women screened for eligibility, 2279 were enrolled (744 in 
SST clusters, 681 in IPT clusters, and 854 in IST clusters). At enrolment, malaria prevalence was lower in IST (5·7%) 
than in SST (12·6%) and IPT (10·6%) clusters. At delivery, malaria prevalence was 20·2% (128 of 633) in SST clusters, 
compared with 11·6% (61 of 528) in IPT clusters (relative risk [RR] 0·59, 95% CI 0·42–0·83, p=0·0022) and 
11·8% (84 of 713) in IST clusters (0·56, 0·40–0·77, p=0·0005). Conditions related to the pregnancy, the puerperium, 
and the perinatal period were the most common serious adverse events for the mothers, and infections and infestations 
for the infants. There were no differences between groups in serious adverse events in the mothers or in their infants.
Interpretation IST was associated with a lower prevalence of malaria than SST at delivery, but the prevalence of malaria 
in this group was also lower at enrolment, making interpretation of the effect of IST challenging. Further studies with 
highly sensitive malaria rapid diagnostic tests should be considered. Monthly IPT with dihydroartemisinin–piperaquine 
is a promising alternative to SST in areas in the Asia-Pacific region with moderate or high transmission of malaria.
Funding Joint Global Health Trials Scheme of the Medical Research Council, Department for International-
Development, and the Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Approximately 70% of 125·2 million pregnancies in 
malaria-endemic areas occur in the Asia-Pacific region 
annually,1 where antenatal infections with Plasmodium 
falciparum and Plasmodium vivax are associated with 
adverse pregnancy outcomes.2–4 In the African region, a 
prevention strategy has been endorsed by WHO, including 
provision of a long-lasting insecticidal net (LLIN) and 
intermittent preventive treatment (IPT) in pregnancy, 
consisting of curative doses of sulfadoxine–pyrimethamine 
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given at every scheduled antenatal visit in the second and 
third trimesters. However, in the Asia-Pacific region, few 
countries have chemoprevention strategies for malaria in 
pregnancy.4 Most provide LLINs as part of antenatal care 
and use single screening and treatment (SST) strategies in 
pregnancy consisting of screening participants for malaria 
infections at the first antenatal visit followed by passive 
case detection, with management of febrile cases.5,6 The 
paucity of chemoprevention strategies reflects the dearth 
of prevention trials and widespread parasite resistance in 
Asia to sulfadoxine–pyrimethamine,7 the only anti malarial 
recommended by WHO for IPT.8
Three completed trials in areas of high sulfadoxine–
pyrimethamine resistance in Kenya and Uganda9–11 
suggest that the fixed-dose, artemisinin-based combination 
therapy of dihydroartemisinin–piperaquine is a promising 
candidate to replace sulfadoxine–pyrimethamine for use 
in IPT. IPT with dihydroartemisinin–piperaquine was 
associated with much greater reductions in malaria 
infection and clinical malaria during pregnancy than was 
IPT with sulfadoxine–pyrimethamine.10
In areas with predominantly low malaria transmission, 
alternative strategies involving regular screening and 
treatment approaches should also be considered. For 
example, in refugee camps on the Thai–Myanmar border, 
the introduction of weekly screening for malaria and 
treatment of pregnant women who tested positive 
reduced maternal mortality from malaria substantially.12 
Such intensive screening programmes are unlikely to be 
feasible under programmatic conditions. However, four 
trials in sub-Saharan Africa showed good feasibility with 
less intensive intermittent screening and treat ment (IST) 
strategies involving malaria rapid diagnostic tests done 
3–6 times during pregnancy.13
Limitations of these screening strategies include the 
failure to detect P falciparum infections that are pre- 
dominantly sequestered in the placenta, or low-grade 
infections that are below the limit of detection by standard 
microscopy or malaria rapid diagnostic tests, which are 
particularly common with P vivax. Furthermore, because 
of the parasite’s dormant forms in the liver, a single P vivax 
infection might cause multiple relapses during pregnancy, 
when radical cure with primaquine is contraindicated. The 
SST strategy has the additional limitation of potentially 
missing re-infections or asymptomatic parasitaemia in 
later stages of pregnancy.
Here, we report the results of the first trial in the 
Asia-Pacific region designed to compare the safety and 
efficacy of monthly IST or IPT with dihydroartemisinin–
piperaquine with the standard SST strategy for decreasing 
the risk of malaria infection in pregnancy.
Methods
Study design and participants
We did an open-label, two-site, three-arm, cluster-
randomised, superiority-trial in areas in eastern 
Indonesia that are co-endemic for P falciparum and 
P vivax: Sumba Island,14,15 which has low malaria 
transmission, and southern Papua, Indonesia,16–18 which 
has moderate year-round transmission (appendix p 4).19,20
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Research in context
Evidence before this study
We searched the Malaria in Pregnancy Library and PubMed from 
their inception to Sept 20, 2018, without language restrictions, 
for relevant trials of chemoprevention with intermittent 
preventive treatment (IPT) or intermittent screening and 
treatment (IST) of malaria in pregnancy. We restricted the search 
to areas in the Asia-Pacific region, Central and South America, the 
horn of Africa, and Madagascar, where Plasmodium falciparum and 
Plasmodium vivax are co-endemic. The following search terms 
were used: “(intermittent OR IPT OR prophylaxis OR prevention) 
AND (malaria OR plasmodium) AND (pregnan* OR trimester OR 
gestation)”. The names of each country in these regions were 
added as additional search terms. Two IPT trials were identified, 
one in the Solomon Islands and the other in Papua New Guinea, 
of which both had used sulfadoxine–pyrimethamine. No IST trials 
were identified. Our literature search confirmed that few 
intermittent screening trials or chemoprevention trials in 
pregnancy have been done outside of Africa. WHO does not have 
a prevention strategy for malaria in pregnancy in the Asia-Pacific 
region, where about 70% of the global number of pregnancies in 
malaria-endemic areas occur. Most countries in this region use a 
single screening and treatment (SST) strategy for malaria at the 
first antenatal visit.
Added value of this study
To our knowledge, this study is the first prevention trial 
to compare monthly IPT or IST with the antimalarial 
dihydroartemisinin-piperaquine against the existing 
SST strategy with dihydroartemisinin–piperaquine for the 
control of malaria in pregnancy in the Asia-Pacific region. 
The study was designed to support the Indonesian Ministry of 
Health and WHO in the development of strategies for the 
control of malaria in pregnancy in Indonesia and the wider 
Asia-Pacific region.
Implications of all the available evidence
Our results do not support a role for IST with the existing 
standard malaria rapid diagnostic tests or for IPT with 
dihydroartemisinin–piperaquine in areas in the Asia-Pacific 
region with lower malaria transmission. However, our results 
confirm earlier findings from east Africa and show that IPT with 
dihydroartemisinin–piperaquine should be considered as a 
potential strategy to reduce the risk of malaria infection, and the 
associated adverse consequences in pregnancy in areas in the 
Asia-Pacific region with moderate to high levels of malaria 
transmission and high levels of resistance to 
sulfadoxine–pyrimethamine.
See Online for appendix
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Antenatal clinics were eligible for inclusion if they had 
at least ten new pregnancies per year and were located 
within 1·5 h drive from the study offices (appendix 
pp 4–5).
Pregnant women of any gravity attending their first 
antenatal visit were eligible if they had a viable pregnancy 
between 16 and 30 weeks’ gestation, were residents in the 
study catchment areas, were willing to complete the 
study schedule and deliver their baby at the study clinics 
or hospital, and had not yet been screened for malaria. 
Exclusion criteria comprised high-risk pregnancies due 
to pre-existing conditions likely to cause complication in 
the current pregnancy (e.g. hypertension, diabetes, 
asthma, renal disease, liver disease, any spinal deformity), 
severe malaria at presentation, treatment with anti-
malarials in the previous month, HIV positivity, a family 
history of sudden death or any known cardiac condition, 
current use of medication known to prolong the 
QTc interval, a history of allergy to dihydroartemisinin–
piperaquine, and residence outside study area or plans to 
move within 6 months.
Ethical approval was obtained from the Liverpool 
School of Tropical Medicine, the Eijkman Institute for 
Molecular Biology, and the National Institute of Health 
Research and Development (Litbangkes), Ministry of 
Health, Jakarta, Indonesia. Written informed consent 
was obtained from all participants. The trial protocol is 
provided in the appendix.
Randomisation and masking
The 78 antenatal clinic clusters were matched in triplicate 
on the basis of location, size, and malaria transmission 
intensity (appendix p 5). Before the study, the 
randomisation sequence to allocate clusters to the three 
intervention arms (1:1:1) was computer generated by the 
study statistician at the Liverpool School of Tropical 
Medicine (appendix pp 5–6) and forwarded to Indonesia. 
The final allocation was achieved during a public 
ceremony in which local health officials drew one of three 
identical looking opaque sealed envelopes which assigned 
their cluster to one of the three study interventions 
(SST, IPT, or IST; appendix pp 5–6). Study participants, 
local study nurses and midwives, and the local study 
coordinators were aware of the treatment allocation. 
Laboratory staff and off-site study investigators, including 
the study statistician, remained masked to treatment 
allocation until after database lock, approval of the 
statistical analysis plan by the Data Monitoring and 
Ethical Committee, and completion of the analytical code 
on the basis of dummy allocation.
Procedures
At enrolment, demographic, socioeconomic, and edu- 
cational information, and data on ownership and use of 
LLINs, were collected, and medical and obstetric histories 
were taken. Gestational age was assessed by fundal height, 
and fetal viability confirmed by doppler ultra sonography. 
The pregnant women’s axillary temperature, blood 
pressure, weight, and mid-upper arm circumference were 
measured, and a blood sample was taken for malaria 
microscopy, molecular malaria diagnostics (quantitative 
PCR [qPCR], nested PCR, and loop-mediated isothermal 
amplification [LAMP]; appendix p 7), immunological 
analyses, and measurement of haemoglobin concentration 
(Haemocue, HemoCue AB, Ängelholm, Sweden). In 
addition, malaria rapid diagnostic tests (First Response 
Malaria Ag pLDH–HRP2 Combo [I16FRC30]; Premier 
Medical Corporation, Nani Daman, India) were done at 
enrolment in all participants in the SST and IST groups, 
regardless of symptoms, and in symptomatic participants 
in the IPT group. All participants received an LLIN. 
Participants were assessed monthly until delivery. At each 
monthly follow-up visit, clinical, obstetric, and physical 
examinations were done, and a blood sample taken by 
fingerprick for malaria microscopy and LAMP–PCR 
(appendix pp 7–8). In addition, malaria rapid diagnostic 
tests were done from the same sample as used for 
microscopy and LAMP-PCR in all participants in the IST 
group, regardless of symptoms, but only in symptomatic 
participants in the SST and IPT groups. Participants were 
encouraged to make unscheduled visits or contact staff if 
they felt ill or were concerned about their pregnancy. 
Participants were assessed for adverse events during each 
scheduled and unscheduled visit.
Participants in the SST clusters were screened 
with malaria rapid diagnostic tests for malaria infection, 
regardless of symptoms, at their first antenatal 
(enrolment) visit only. At subsequent monthly visits, they 
were tested with malaria rapid diagnostic tests if they 
were febrile (axillary temperature ≥37·5°C) or had a 
history of fever in the previous 48 h. The procedures in 
the IST group were identical to those in the SST group, 
except that participants were screened with malaria rapid 
diagnostic tests at each scheduled monthly visit. 
Participants in the IPT group received 4 mg/kg per day 
dihydroartemisinin and 18 mg/kg per day piperaquine 
(in 40 mg/320 mg tablets; Eurartesim, Sigma-Tau, Rome, 
Italy) at each monthly visit, at which they were not 
screened for malaria, unless they were febrile or had a 
history of fever in the past 48 h. The dose was the same 
throughout pregnancy and consisted of the standard 
3-day course of two tablets for participants weighing less 
than 36 kg, three tablets for participants weighing 
36–75 kg, or four tablets for participants weighing 75 kg 
or more at enrolment. The first dose was provided with a 
glass of water as directly observed therapy in the clinic. 
Participants were provided with the remaining two doses 
to be taken at home. All participants were contacted on 
day 2 and visited on day 3 to assess adherence and 
tolerance. In case of vomiting within 30 min, the full 
dose was repeated. Additionally, all participants who 
were positive for malaria on rapid diagnostic tests 
(positive HRP2 or pLDH bands) in all groups were 
treated with dihydroartemisinin–piperaquine (the same 
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3-day weight-based treatment as used for the IPT group). 
Participants with a history of dihydroartemisinin–
piperaquine intake in the previous 4 weeks received 
quinine–clindamycin (10 mg/kg twice daily for 7 days).
At delivery, a maternal blood sample was taken for the 
same malaria metrics, and placental and umbilical-cord 
blood samples for histology, malaria rapid diagnostic tests, 
microscopy, and LAMP and PCR (appendix pp 7–8). 
Newborns were weighed on a digital scale (±10 g) and their 
gestational age assessed by means of the modified Ballard 
score.21 The presence of jaundice and congenital anomalies 
detectable by surface examination were assessed at 
delivery, day 7, and the final visit at 6–8 weeks. In between 
scheduled visits, infants were followed up passively.
We extracted DNA from dried blood spots using the 
Chelex method and tested for malaria using LAMP Pan-
kits. LAMP-positive samples and 5% of negative samples 
were then tested by qPCR for verification and species 
identification, and discordant samples retested with 
nested-PCR (appendix pp 7–8).
Electrocardiography was done in a subgroup of 
33 participants in the IPT group (selected through 
convenience sampling) to establish whether previously 
documented transient QTc prolongation associated with 
piperaquine increased in magnitude with subsequent 
courses (appendix p 10).
Outcomes
The primary outcome was malaria (any species) at delivery, 
defined as a composite of maternal malaria (detection of 
infection in peripheral blood with microscopy, rapid 
diagnostic test, or LAMP–PCR) or placental malaria 
(detection of infection in placental blood with microscopy, 
LAMP–PCR, or histology [active infection]; appendix 
pp 6–8).
Secondary outcomes at delivery comprised the 
individual components of the primary composite out-
come (maternal or placental malaria), detected by any 
method and by each method separately. Placental malaria 
infection detected by histology was classified as active 
acute, active chronic, active any, past, or any (active or 
past). In post-hoc analyses, malaria infection in the 
peripheral blood was stratified further by species. In 
addition, maternal anaemia (any: haemoglobin level 
<11 g/dL; moderate: haemoglobin level <9 g/dL) was 
assessed at delivery.
Secondary outcomes during pregnancy comprised 
maternal malaria, detected with any method and by each 
method separately. This outcome was further stratified 
by patent infection (positive microscopy or malaria rapid 
diagnostic test) and sub-patent infection (negative 
microscopy and malaria rapid diagnostic test and positive 
LAMP–PCR). Morbidity outcomes assessed during 
pregnancy comprised clinical malaria (documented or 
history of fever plus positive malaria rapid diagnostic test 
or microscopy) and unscheduled clinic visits for any 
reason and for all reasons unrelated to malaria.
Newborn secondary efficacy outcomes included 
congenital malaria, mean cord haemoglobin concentration, 
fetal anaemia (haemoglobin <12·5 g/dL), mean 
birthweight, low birthweight (<2500 g), mean gestational 
age, preterm delivery (<37 weeks’ gestation), mean 
birthweight for gestational age (Z scores), small 
for gestational age,22 fetal loss (spontaneous abortion at 
<28 weeks’ gestation or stillbirth), and the composite 
outcomes of adverse livebirth (preterm, low birthweight, 
or small for gestational age) and adverse pregnancy 
(adverse livebirth or fetal loss). Other secondary efficacy 
outcomes in the infant included the incidence of clinical 
malaria and all-cause and non-malaria illness by the end of 
follow-up (age 6–8 weeks). Mortality outcomes included 
neonatal, perinatal, and mortality up to age 6–8 weeks.
Safety outcomes included serious adverse events in the 
mother or infant, overall and by system organ class and 
preferred Medical Dictionary of Regulatory Affairs term; 
maternal deaths; congenital anomalies; and QTc pro-
longation.
Statistical analysis
The trial was initially designed to detect a 50% reduction 
in malaria at delivery with IPT or with IST relative 
to SST across both sites pooled. Following reco- 
mmendations from the ethics committee in Indonesia 
on June 27, 2014, to stop recruitment in Sumba because 
of the unexpected low malaria prevalence in the area, a 
blinded interim re-estimation of sample size was done 
with the aim to provide the study with 80% power across 
both sites pooled and 85% power in Papua alone to 
detect at least a 50% reduction in the primary outcome 
(two-sided α value of 0·0167, intracluster correlation 
coefficient of 0·005; appendix p 9). The revised study 
required 2279 participants (1290 from Papua and 
989 from Sumba), accounting for a 13% efficiency loss 
owing to varying cluster sizes and 20% loss to follow-up.
The modified intention-to-treat (ITT) population 
included all randomised participants with outcome data. 
We also assessed all efficacy outcomes in the per-protocol 
population, which included participants in the modified 
ITT population who attended every scheduled visit and 
took all study doses on each occasion. The safety-
population included participants who received at least 
one dose of study drug in any of the study arms.
Generalised estimating equation (GEE) models, with 
treatment group as a predictor and clinic as a cluster 
effect, were used. Log binomial GEE models were used to 
obtain risk ratios (RRs) for binary outcomes (including 
the cumulative risk), and linear GEE models to obtain 
mean differences for continuous outcomes. The 
unadjusted analysis, stratified by site, was considered the 
primary analysis. Because matching was ineffective and 
the number of triplets small in each site, unmatched 
analysis of the matched data was done to maximise 
power as soon as it became clear from the comparison of 
the baseline data that the matching was not successful.23,24 
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Separate models were run per site (pre-planned), and 
differences in treatment effects compared by means of 
the Altman-Bland method.25
Secondary, covariate-adjusted analyses of the efficacy 
endpoints were done with seven prespecified, individual-
level covariates and one post-hoc, cluster-level covariate 
(prevalence of malaria infection at enrolment as a proxy 
for malaria transmission). The individual-level covariates 
were study site (overall models only), malaria status at 
enrolment (binary), season during pregnancy (terciles 
based on average rainfall during the last 6 months of 
pregnancy), socioeconomic status (terciles of Socioe-
conomic Index27], calculated with principal component 
analysis), gestational age at enrolment (binary, based 
on the median value), gravidity (primigravidae or 
secundigravidae vs multi gravidae), and use of insecticide-
treated net during pregnancy. Simple imputation was 
used for missing covariates (<1%); no imputation was 
used for missing outcome variables. These same 
covariates, as well as a post-hoc covariate for species on 
enrolment, were used for subgroup analyses by adding 
them as interaction terms with treatment group. GEE 
Poisson regression, with time of follow-up as an offset, 
was used to obtain incidence rate-ratios.
The analysis was done with SAS version 9.3 and Stata 
version 14. The Data Monitoring and Ethical Committee 
oversaw the study. A cost-effectiveness analysis will 
be published elsewhere. The trial was registered with 
ISRCTN, number ISRCTN34010937.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RA, CK, FOtK, TC, and DW had full 
Figure 1: Trial profile
IPT=intermittent preventive treatment. IST=intermittent screening and treatment. SST=single screening and treatment. *The number of recruited participants 
per cluster was restricted to a maximum of five per day to keep the number needed to follow-up manageable in subsequent visits. On some days, more than 
five participants were eligible, in which case they were chosen at random by drawing lots among all eligible participants who presented that morning.
26 assigned to SST 
(880 women screened)
135 women excluded
 91 not eligible
 44 eligible, not included*
744 recruited
111 excluded
 9 withdrew consent
 66 lost to follow-up
 34 missed delivery
 2 screening error
 0 death
633 contributed to
         primary analysis
461 contributed to 
 per-protocol analysis
172 excluded
 31 non-adherence to regimen
 8 prohibited medication
 133 missed a scheduled visit
26 assigned to IST
(1441 women screened)
78 clusters randomly assigned
90 clusters assessed for eligibility
587 women excluded
 531 not eligible
 56 eligible, not included*
12 did not meet inclusion criteria
854 recruited
141 excluded
 11 withdrew consent
 95 lost to follow-up
 32 missed delivery
 2 screening error
 1 death
713 contributed to
         primary analysis
519 contributed to
 per-protocol analysis
194 excluded
 36 non-adherence to regimen
 9 prohibited medication
 149 missed a scheduled visit
26 assigned to IPT 
(1232 women screened)
551 women excluded
 510 not eligible
 41 eligible, not included*
681 recruited
153 excluded
 62 withdrew consent
 53 lost to follow-up
 35 missed delivery
 3 screening error
 0 death
528 contributed to
         primary analysis
362 contributed to 
 per-protocol analysis
166 excluded
 45 non-adherence to regimen
 0 prohibited medication
 121 missed a scheduled visit
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access to all the data in the study. The corresponding 
author had final responsibility for the decision to submit 
for publication.
Results
Between May-16, 2013, and April-21, 2016 (when the 
required sample size was reached), 78 clusters (57 in 
Sumba and 21 in Papua) were randomly assigned to SST, 
IPT, or IST (26 clusters each). 3553 women were 
screened for inclusion, of whom 2279 (64·1%) were 
enrolled (989 from Sumba and 1290 from Papua; 
figure-1). The last delivery occurred on Oct-9, 2016, and 
the last infant follow-up on Nov-26, 2016. Overall, 
7350 (85·4%) of 8609 scheduled antenatal visits were 
Sumba Papua Pooled sites
SST (n=337) IST (n=359) IPT (n=293) SST (n=407) IST (n=495) IPT (n=388) SST (n=744) IST (n=854) IPT (n=681)
Maternal age, years 28·1 (6·1) 27·8 (5·9) 28 (6·0) 26 (6·1) 25·9 (6·7) 25·8 (6·0) 27 (6·2) 26·7 (6·4) 26·8 (6·1)
Residence, 
rural vs semi-urban
95·0% 
(320/337)
91·1% 
(327/359)
90·1% 
(264/293)
59·2% 
(241/407)
67·9% 
(336/495)
58·0% 
(225/388)
75·4% 
(561/744)
77·6% 
(663/854)
71·8% 
(489/681)
Marital status, 
single* vs married
62·3% 
(210/337)
65·2% 
(234/359)
63·1% 
(185/293)
34·6% 
(141/407)
27·1% 
(134/495)
35·3% 
(137/388)
47·2% 
(351/744)
43·1% 
(368/854)
47·3% 
(322/681)
Used a bednet previous 
night
22·3% 
(75/337)
25·3% 
(91/359)
22·5% 
(66/293)
49·4% 
(201/407)
45·7% 
(226/495)
53·1% 
(206/388)
37·1% 
(276/744)
37·1% 
(317/854)
39·9% 
(272/681)
Attended school 91·1% 
(307/337)
87·2% 
(313/359)
88·1% 
(258/293)
86·0% 
(350/407)
94·7% 
(469/495)
89·4% 
(347/388)
88·3% 
(657/744)
91·6% 
(782/854)
88·8% 
(605/681)
Schooling level†
Low 22·0% 
(74/337)
23·4% 
(84/359)
22·9% 
(67/293)
22·1% 
(90/407)
11·7% 
(58/495)
15·5% 
(60/388)
22·0% 
(164/744)
16·6% 
(142/854)
18·6% 
(127/681)
Medium 30·9% 
(104/337)
25·9% 
(93/359)
26·3% 
(77/293)
18·2% 
(74/407)
16·2% 
(80/495)
13·4% 
(52/388)
23·9% 
(178/744)
20·3% 
(173/854)
18·9% 
(129/681)
High 21·1% 
(71/337)
23·1% 
(83/359)
28·0% 
(82/293)
22·6% 
(92/407)
24·2% 
(120/495)
18·8% 
(73/388)
21·9% 
(163/744)
23·8% 
(203/854)
35·8% 
(244/681)
Highest 26·1% 
(88/337)
27·6% 
(99/359)
22·9% 
(67/293)
37·1% 
(151/407)
47·9% 
(237/495)
52·3% 
(203/388)
32·1% 
(239/744)
39·3% 
(336/854)
39·6% 
(270/681)
Socioeconomic Index score, terciles
Low 34·4% 
(116/337)
32·0% 
(115/359)
33·4% 
(98/293)
43·5% 
(177/407)
30·1% 
(149/495)
26·8% 
(104/388)
39·4% 
(293/744)
30·9% 
(264/854)
29·7% 
(202/681)
Medium 32·6% 
(110/337)
33·4% 
(120/359)
34·8% 
(102/293)
32·4% 
(132/407)
33·1% 
(164/495)
34·3% 
(133/388)
32·5% 
(242/744)
33·3% 
(284/854)
34·5% 
(235/681)
High 32·9% 
(111/337)
34·5% 
(124/359)
31·7% 
(93/293)
24·1% 
(98/407)
36·8% 
(182/495)
38·9% 
(151/388)
28·1% 
(209/744)
35·8% 
(306/854)
35·8% 
(244/681)
Pregnancy number, gravidity
One 28·2% 
(95/337)
28·7% 
(103/359)
28·0% 
(82/293)
26·0% 
(106/407)
26·5% 
(131/495)
29·6% 
(115/388)
27·0% 
(201/744)
27·4% 
(234/854)
28·9% 
(197/681)
Two 22·3% 
(75/337)
24·0% 
(86/359)
20·5% 
(60/293)
29·2% 
(119/407)
31·5% 
(156/495)
29·1% 
(113/388)
26·1% 
(194/744)
28·3% 
(242/854)
25·4% 
(173/681)
Three or more 49·6% 
(167/337)
47·4% 
(170/359)
51·5% 
(151/293)
44·7% 
(182/407)
42·0% 
(208/495)
41·2% 
(160/388)
46·9% 
(349/744)
44·3% 
(378/854)
45·7% 
(311/681)
Gestational age, weeks 24·1 (4·6) 24·1 (4·3) 24·1 (4·6) 23·7 (5·3) 22·8 (5·1) 23·8 (4·5) 23·9 (5) 23·4 (4·8) 23·9 (4·6)
Weight, kg 51·9 (7·0) 51·3 (6·8) 52·0 (8·1) 56·7 (5·3) 56·0 (9·6) 57·8 (9·4) 54·5 (8·6) 54·0 (8·8) 55·3 (9·3)
Height, cm 152·4 (5·4) 152·5 (5·6) 151·8 (6·3) 152·7 (5·3) 152·8 (5·5) 152·8 (5·3) 152·6 (5·3) 152·7 (5·5) 152·3 (5·8)
Mid-upper arm 
circumference, cm
24·6 (2·8) 24·2 (2·4) 24·7 (2·7) 25·3 (3·1) 25·6 (3·4) 25·8 (3·2) 25·0 (3·0) 25·0 (3·1) 25·3 (3·0)
Haemoglobin, g/dL 11·0 (1·4) 11·0 (1·6) 11·1 (1·5) 11·0 (1·9) 11·7 (1·8) 11·4 (1·9) 11·0 (1·7) 11·4 (1·8) 11·3 (1·7)
Plasmodium infection
mRDT‡ 0·3% 
(1/337)
0·0% 
(0/359)
0·0% 
(0/2)
7·4% 
(30/407)
3·0% 
(15/495)
50·0% 
(3/6)
4·2% 
(31/744)
1·8% 
15/854)
37·5% 
(3/8)
Microscopy 0·6% 
(2/337)
0·3% 
(1/358)
0·7% 
(2/293)
9·1% 
(37/407)
3·6% 
(18/495)
5·9% 
(23/387)
5·2% 
(39/744)
2·2% 
(19/853)
3·7% 
(25/680)
LAMP–PCR 6·5% 
(22/337)
2·8% 
(10/359)
8·6% 
(25/290)
11·8% 
(48/407)
5·9% 
(29/495)
9·0% 
(35/387)
9·4% 
(70/744)
4·6% 
(39/854)
8·9% 
(60/677)
Any§ 6·5% 
(22/337)
3·1% 
(11/359)
8·5% 
(25/293)
17·7% 
(72/407)
7·7% 
(38/495)
12·1% 
(47/388)
12·6% 
(94/744)
5·7% 
(49/854)
10·6% 
(72/681)
(Table 1 continues on next page)
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attended (appendix p 12). At baseline, 215 (9·4%) of 
2279 participants had peripheral parasitaemia; the 
prevalence was similar in the SST (94 [12·6%] of 744) 
and IPT (72 [10·6%] of 681) groups, but lower in the IST 
group (49 [5·7%] of 854; table-1). Overall 418 (90%) of 
463 cases of peripheral parasitaemia detected by 
LAMP–PCR were below the limit of detection for malaria 
rapid diagnostic tests.
Median follow-up was 3·1 months (IQR 2·1–4·0), with 
a median number of scheduled follow-up visits of three 
(range 1–6; appendix p 12). The median number of 
dihydroartemisinin–piperaquine courses in the IPT 
group was three (range 0–6). Ultimately, 1874 (82·2%) of 
2279 women contributed to the primary endpoint 
(figure-1). These proportions did not differ significantly 
overall, but in Papua the proportion of enrolled 
participants who contributed to the primary endpoint 
was significantly lower in IPT clusters (70·1%) than in 
SST (84·3%; p=0·0005) and IST (86·5%) clusters 
(p<0·0001), whereas in Sumba it was lower in IST 
clusters (79·4%) than in IPT (87·4%; p=0·017) or SST 
(86·1%; p=0·070) clusters (appendix pp 14, 31).
The prevalence of malaria at delivery in the modified 
ITT population was 20·2% (128 of 633) in SST clusters 
compared with 11·6% (61 of 528) in IPT clusters 
(RR 0·59, 95% CI 0·42–0·83; p=0·0022) and 11·8% 
(84 of 713) in IST clusters (0·56, 0·40–0·77; p=0·0005; 
figures 2, 3). There was no significant difference in the 
prevalence of malaria at delivery between IPT and IST 
clusters (1·06, 0·73–1·54, p=0·77; figure-4). Similar 
results were obtained in covariate-adjusted analyses 
(figures-2–4), across all subgroups (appendix pp 32–34), 
in the per-protocol population (appendix pp 35–37), and 
in a post-hoc sensitivity analysis with matched analysis 
(appendix p 15). Intracluster correlation coefficient values 
are shown in appendix p 16.
Analyses of secondary outcomes at delivery showed 
that relative to SST, IPT was associated with a reduction 
in patent infections and sub-patent infections in 
peripheral blood (figure-2; appendix p 38). For IST, the 
reduction was significant for sub-patent infections only 
(figure-3; appendix p 39). The prevalence of placental 
malaria detected by histology (active or past) or other 
methods was lower in IPT clusters than in SST clusters 
(appendix p 41). It was similar in IPT and IST clusters in 
the unadjusted analysis but lower in IST than in IPT 
clusters in the adjusted analysis (figure 4), owing to 
reductions in past infections with IPT (appendix p 43). 
There were no significant differences in malaria detected 
by placental histology between IST and SST (appendix 
p 42).
Analyses of secondary outcomes during pregnancy 
showed that the cumulative risk of incident malaria 
infection during pregnancy detected by at least one 
diagnostic method was lower in IPT than in SST clusters 
(figure 2). Similar results were seen for other definitions 
of antenatal malaria infection (appendix p 44). The 
cumulative risk of clinical malaria was also lower with 
IPT than with SST (figure 2). The cumulative risk of 
malaria detected by rapid diagnostic test was not 
significantly different between IPT and SST clusters 
(appendix p 42). In the IST clusters, by contrast, the 
antenatal incidence measures of malaria infection were 
similar to those in SST clusters (figure 3; appendix 
p 45). The cumulative proportion of participants with 
malaria infection detected by malaria rapid diagnostic 
test (including at enrolment) was also similar between 
IST and SST (34 [4·0%] of 854) and SST (39 [5·2%] 
of 744) groups (RR 0·91, 95% CI 0·36–2·32, p=0·84), 
despite the nearly four times higher number of 
screening events in IST than in SST clusters 
(2886 vs 744). The incidence of clinical malaria with IST 
Sumba Papua Pooled sites
SST (n=337) IST (n=359) IPT (n=293) SST (n=407) IST (n=495) IPT (n=388) SST (n=744) IST (n=854) IPT (n=681)
(Continued from previous page)
Infecting species¶
Plasmodium falciparum, 
mono-infection
3·3% 
(11/337)
1·1% 
(4/359)
5·1% 
(15/292)
8·1% 
(33/407)
4·0% 
(20/495)
7·7% 
(30/388)
5·9% 
(44/744)
2·8% 
(24/854)
6·6% 
(45/680)
Plasmodium vivax, 
mono-infection
2·4% 
(8/337)
1·7% 
(6/359)
2·1% 
(6/292)
5·2% 
(21/407)
2·4% 
(12/495)
1·8% 
(7/388)
3·9% 
(29/744)
2·1% 
(18/854)
1·9% 
(13/680)
Plasmodium malariae 
or Plasmodium ovale, 
mono-infection
0·0% 
(0/337)
0·0% 
(0/359)
0·0% 
(0/292)
1·0% 
(4/407)
0·0% 
(0/495)
0·0% 
(0/388)
0·5% 
(4/744)
0·0% 
(0/854)
0·0% 
(0/680)
Mixed infection 0·6% 
(2/337)
0·3% 
(1/359)
0·7% 
(2/292)
3·4% 
(14/407)
1·2% 
(6/495)
2·6% 
(10/388)
2·2% 
(16/744)
0·8% 
(7/854)
1·8% 
(12/680)
Data are mean (SD) or % (n/N). SST=single screen and treatment. IST=intermittent screen and treatment. IPT=intermittent preventive therapy. mRDT=malaria rapid diagnostic 
test. LAMP=loop-mediated isothermal amplification. *Single includes single unmarried participants only as there were no divorced, separated, or widowed participants. In 
Sumba, many participants were not legally married, but co-habiting with their partner and considered married within their local communities. †Low was defined as no 
schooling or primary school not completed, medium as primary school completed, high as junior high school completed, and highest as senior high school or tertiary 
education completed. ‡Data reflect mRDTs done in symptomatic participants in the IPT group and all participants in the SST and IST groups. §Includes mRDT results from 
symptomatic participants and microscopy and LAMP–PCR results from all participants. ¶Typing was done by PCR; if PCR was not successful, species was based on microscopy.
Table-1: Baseline characteristics of enrolled participants
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Figure 2: IPT versus SST for the primary outcome and key secondary outcomes, overall and by site (modified ITT population)
ITT=intention to treat. LAMP=loop-mediated isothermal amplification. IPT=intermittent preventive treatment. SST=single screening and treatment. RR=relative risk. *Adjusted for site (in the overall 
models only) and six additional, prespecified, participant-level covariates. †Detected by LAMP, PCR, microscopy, or malaria rapid diagnostic test. ‡Detected by LAMP, PCR, microscopy, malaria rapid 
diagnostic test, or histology (active and past infection). §Defined as fetal loss, low birthweight, small for gestational age, or preterm birth.
Favours SSTFavours IPT
Overall
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dL at delivery
Fetal anaemia (cord haemoglobin <12·5 g/dL) 
Small for gestational age (<10th percentile22)
Low birthweight (<2500 g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
Adverse pregnancy outcome§
Sumba
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dL at delivery
Fetal anaemia (cord haemoglobin <12·5  g/dL) 
Small for gestational age (<10th percentile22)
Low birthweight (<2500g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
Adverse pregnancy outcome§
Papua
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dl at delivery
Fetal anaemia (cord haemoglobin <12·5 g/dL)
Small for gestational age (<10th percentile22)
Low birthweight (<2500g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
Adverse pregnancy outcome§
IPT vs SST
 61/528 (11·6%)
 
 53/595 (8·9%)
 2/595 (0·3%)
 1/523 (0·2%)
 28/523 (5·4%)
 40/500 (8·0%)
 60/524 (11·5%)
 85/487 (17·5%)
 69/512 (13·5%)
 93/512 (18·2%)
 61/524 (11·6%)
 13/561 (2·3%)
 5/524 (1·0%)
 153/561 (27·3%)
 29/256 (11·3%)
 
 36/276 (13·0%)
 
 0/276 
 
 0/253 
 
 17/253 (6·7%)
 
 15/249 (6·0%)
 34/254 (13·4%)
 30/243 (12·3%)
 40/243 (16·5%)
 62/243 (25·5%)
 37/250 (14·8%)
 8/258 (3·1%)
 0/250 
 94/258 (36·4%)
 32/272 (11·8%)
 
 17/319 (5·3%)
 2/319 (0·6%)
 1/270 (0·4%)
 11/270 (4·1%)
 25/251 (10·0%)
 26/270 (9·6%)
 55/244 (22·5%)
 29/269 (10·8%)
 31/269 (11·5%)
 24/274 (8·8%)
 5/303 (1·7%)
 5/274 (1·8%)
 59/303 (19·5%)
IPT n/N (%)
 128/633 (20·2%)
 
118/680 (17·4%)
 13/680 (1·9%)
 14/627 (2·2%)
 56/627 (8·9%)
 95/610 (15·6%)
 93/631 (14·7%)
 139/603 (23·1%)
 71/625 (11·4%)
 86/626 (13·7%)
 70/635 (11·0%)
 9/662 (1·4%)
 7/634 (1·1%)
 151/663 (22·8%)
 47/290 (16·2%)
 
 40/324 (12·3%)
 
 0/324
 
 1/284 (0·4%)
 
 28/284 (9·9%)
 
 20/283 (7·1%)
 41/289 (14·2%)
 47/278 (16·9%)
 37/287 (12·9%)
 42/287 (14·6%)
 32/289 (11·1%)
 4/293 (1·4%)
 0/288 
 75/293 (25·6%)
 81/343 (23·6%)
 
78/356 (21·9%)
 13/356 (3·7%)
 13/343 (3·8%)
 28/343 (8·2%)
 75/327 (22·9%)
 52/342 (15·2%)
 92/325 (28·3%)
 34/338 (10·1%)
 44/339 (13·0%)
 38/346 (11·0%)
 5/369 (1·4%)
 7/346 (2·0%)
 76/370 (20·5%)
SST, n/N (%)
0·59 (0·42–0·83)
0·60 (0·39–0·92)
0·22 (0·05–0·98)
0·09 (0·01–0·60)
0·60 (0·39–0·93)
0·58 (0·36–0·94)
0·79 (0·61–1·02)
0·75 (0·55–1·01)
1·18 (0·86–1·61)
1·35 (0·97–1·87)
1·06 (0·74–1·53)
1·72 (0·68–4·32)
0·82 (0·17–3·90)
1·23 (0·97–1·55)
0·0022
0·018
0·048
0·013
0·022
0·026
0·070
0·060
0·32
0·070
0·74
0·25
0·80
0·090
0·0026
<0·0001
0·012
0·012
0·0046
0·0006
0·016
0·11
0·73
0·50
0·43
0·91
0·84
0·58
0·63 (0·48–0·83)
0·60 (0·40–0·89)
0·21 (0·05–0·82)
0·09 (0·01–0·58)
0·65 (0·43–0·99)
0·51 (0·35–0·75)
0·80 (0·63–1·03)
0·79 (0·63–0·99)
1·25 (0·98–1·60)
1·40 (1·05–1·86)
1·13 (0·81–1·56)
1·76 (0·71–4·34)
0·94 (0·21–4·25)
1·27 (1·06–1·53)
0·72 (0·48–1·09)
1·08 (0·70–1·68)
··
··
0·68 (0·37–1·25)
0·94 (0·52–1·72)
0·88 (0·66–1·17)
0·73 (0·46–1·14)
1·38 (0·94–2·02)
1·84 (1·35–2·51)
1·38 (0·88–2·16)
2·29 (0·66–7·96)
··
1·45 (1·16–1·83)
0·55 (0·39–0·77)
0·23 (0·14–0·39)
0·16 (0·04–0·67)
0·09 (0·02–0·56)
0·65 (0·42–1·00)
0·44 (0·27–0·73)
0·72 (0·53–0·97)
0·77 (0·56–1·04)
1·28 (0·84–1·96)
0·72 (0·40–1·31)
0·77 (0·40–1·47)
1·42 (0·36–5·56)
0·86 (0·21–3·43)
0·93 (0·58–1·48)
Adjusted RR
(95% CI)*
0·0011
0·011
0·025
0·011
0·043
0·0007
0·080
0·043
0·080
0·021
0·47
0·22
0·93
0·011
0·12
0·72
··
··
0·21
0·84
0·37
0·16
0·10
0·16
0·19
··
0·0014
0·0006
0·012
0·0099
0·047
0·0014
0·033
0·09
0·25
0·28
0·43
0·62
0·82
0·75
p value
0·70 (0·44–1·09)
1·05 (0·62–1·78)
··
··
0·68 (0·37–1·26)
0·90 (0·49–1·66)
0·91 (0·68–1·23)
0·73 (0·46–1·16)
1·32 (0·90–1·95)
1·77 (1·29–2·42)
1·33 (0·86–2·07)
2·25 (0·67–7·57)
··
1·43 (1·13–1·79)
0·50 (0·32–0·79)
0·23 (0·14–0·39)
0·16 (0·04–0·67)
0·10 (0·02–0·60)
0·51 (0·32–0·81)
0·43 (0·26–0·69)
0·64 (0·44–0·92)
0·79 (0·59–1·06)
1·08 (0·71–1·63)
0·84 (0·51–1·40)
0·77 (0·41–1·46)
1·08 (0·29–3·96)
0·86 (0·22–3·45)
0·90 (0·60–1·33)
Crude RR
(95% CI)
0·12
0·85
··
··
0·22
0·74
0·55
0·18
0·16
0·0004
0·21
0·19
··
0·0024
p value
0 0·5 1 1·5 2 2·5 3
<0·0001
<0·0001
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Figure 3: IST versus SST in the primary outcome and key secondary outcomes, overall and by site (modified ITT population)
ITT=intention to treat. LAMP=loop-mediated isothermal amplification. IST=intermittent screening and treatment. SST=single screening and treatment. RR=relative risk. *Adjusted for site (in the 
overall models only) and six additional, prespecified, participant-level covariates. †Detected by LAMP, PCR, microscopy, or malaria rapid diagnostic test. ‡Detected by LAMP, PCR, microscopy, malaria 
rapid diagnostic test, or histology (active and past infection). §Defined as fetal loss, low birthweight, small for gestational age, or preterm birth.
 0·43 (0·24–0·78)
 1·11 (0·65–1·90)
 
 ··
 
 1·01 (0·07–15·17)
 0·21 (0·11–0·43)
 0·87 (0·50–1·51)
 1·11 (0·87–1·43)
 0·76 (0·53–1·08)
 1·00 (0·68–1·48)
 1·08 (0·76–1·54)
 1·45 (0·95–2·20)
 1·98 (0·60–6·50)
 ··
 1·18 (0·92–1·52)
 v0·85 (0·65–1·11)
 0·67 (0·41–1·09)
 0·39 (0·18–0·88)
 0·66 (0·33–1·29)
 1·02 (0·67–1·54)
 0·90 (0·70–1·14)
 0·87 (0·61–1·25)
 0·78 (0·61–1·00)
 0·89 (0·57–1·39)
 0·56 (0·28–1·12)
 0·56 (0·35–0·90)
 2·04 (0·56–7·41)
 0·65 (0·21–2·02)
 0·77 (0·44–1·37)
Favours SSTFavours IST
Overall
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dL at delivery
Fetal anaemia (cord haemoglobin <12·5 gd/L)
Small for gestational age (<10th percentile22)
Low birthweight (<2500 g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
Adverse pregnancy outcome§
Sumba
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dL at delivery
Fetal anaemia (cord haemoglobin <12·5  g/dL) 
Small for gestational age (<10th percentile22)
Low birthweight (<2500g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
Adverse pregnancy outcome§
Papua
Maternal peripheral or placental plasmodium infection
at delivery (primary outcome)
Maternal plasmodium infection during pregnancy†
(cumulative risk)
Maternal clinical malaria during pregnancy
(cumulative risk)
Maternal peripheral patent plasmodium infection
at delivery
Maternal peripheral sub-patent plasmodium infection
at delivery
Placental plasmodium infection‡
Maternal haemoglobin <9 g/dl at delivery
Fetal anaemia (cord haemoglobin <12·5 g/dL)
Small for gestational age (<10th percentile22)
Low birthweight (<2500g)
Preterm birth (<37 weeks)
Fetal loss (spontaneous abortion or stillbirth)
Neonatal death (<28 days)
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Figure 4: IPT versus IST in the primary outcome and key secondary outcomes, overall and by site (modified ITT population)
LAMP=loop-mediated isothermal amplification. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. RR=relative risk.*Adjusted for site (in the overall models only) 
and six additional, prespecified, participant-level covariates. †Detected by LAMP, PCR, microscopy, or malaria rapid diagnostic test. ‡Detected by LAMP, PCR, microscopy, malaria rapid diagnostic test, 
or histology (active and past infection). §Defined as fetal loss, low birthweight, small for gestational age, or preterm birth
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(cumulative risk)
Maternal clinical malaria during pregnancy
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at delivery
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was lower than with SST, but this difference was not 
significant (figure 3; appendix p 45). Relative to IST, IPT 
was significantly more effective in preventing malaria 
infections during pregnancy (figure-4; appendix p 46). 
Non-malaria outcomes were similar between the IPT 
and IST groups (appendix p 46).
There were some significant differences in the effects 
on the malaria infection outcomes by study site 
IPT (n=681 women, n=524 infants)* IST (n=854 women, n=712 infants)† SST (n=744 women, n=634 infants)‡
Number of 
participants 
with event (%)
Total 
number 
of events
Incidence 
per 100 person-years 
(95% CI)
Number of 
participants 
with event (%)
Total 
number 
of events
Incidence per 
100 person-years 
(95% CI)
Number of 
participants 
with event (%)
Total 
number 
of events
Incidence per 
100 person-years 
(95% CI)
Mothers
Any serious adverse event 56 (8·2%) 85 54·2 (43·3–67·1) 77 (9·0%) 105 47·2 (38·6–57·2) 71 (9·5%) 113 60·4 (49·8–72·6)
Pregnancy, puerperium and 
perinatal conditions
47 (6·9%) 62 39·6 (30·3–50·7) 60 (7·0%) 71 31·9 (25–40·3) 51 (6·9%) 65 34·7 (26·8–44·3)
Infections and infestations 8 (1·2%) 8 5·1 (2·2–10·1) 9 (1·1%) 11 4·9 (2·5–8·9) 17 (2·3%) 26 13·9 (9·1–20·4)
Gastrointestinal disorders 2 (0·3%) 3 1·9 (0·4–5·6) 1 (0·1%) 2 0·9 (0·1–3·3) 2 (0·3%) 3 1·6 (0·3–4·7)
Surgical and medical procedures 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 1 (0·1%) 1 0·5 (0–3)
Blood and lymphatic system 
disorders
7 (1·0%) 7 4·5 (1·8–9·2) 12 (1·4%) 14 6·3 (3·4–10·6) 15 (2·0%) 15 8 (4·5–13·2)
Nervous system disorders 0 0 0 (0–0) 0 0 0 (0–0) 1 (0·1%) 2 1·1 (0·1–3·9)
Reproductive system and breast 
disorders
1 (0·1%) 1 0·6 (0–3·6) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Injury, poisoning and procedural 
complications
0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Respiratory, thoracic and 
mediastinal disorders
1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Vascular disorders 1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Metabolism and nutrition disorders 1 (0·1%) 1 0·6 (0–3·6) 2 (0·2%) 2 0·9 (0·1–3·3) 0 0 0 (0–0)
Hepatobiliary disorders 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 0 0 0 (0–0)
Cardiac disorders 0 0 0 (0–0) 1 (0·1%) 1 0·4 (0–2·5) 1 (0·1%) 1 0·5 (0–3)
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps)
1 (0·1%) 1 0·6 (0–3·6) 0 0 0 (0–0) 0 0 0 (0–0)
Infants
Any serious adverse event 40 (7·6%) 56 88 (66·5–114·3) 53 (7·4%) 75 89·5 (70·4–112·2) 51 (8·0%) 69 86·5 (67·3–109·5)
Congenital, familial and 
genetic disorders
11 (2·1%) 11 17·3 (8·6–30·9) 18 (2·5%) 19 22·7 (13·7–35·4) 19 (3·0%) 19 23·8 (14·3–37·2)
Pregnancy, puerperium and 
perinatal conditions
6 (1·1%) 6 9·4 (3·5–20·5) 14 (2·0%) 14 16·7 (9·1–28) 10 (1·6%) 12 15 (7·8–26·3)
Infections and infestations 18 (3·4%) 19 29·9 (18–46·6) 23 (3·2%) 23 27·5 (17·4–41·2) 24 (3·8%) 25 31·4 (20·3–46·3)
Gastrointestinal disorders 0 0 0 (0–0) 1 (0·1%) 1 1·2 (0–6·7) 2 (0·3%) 2 2·5 (0·3–9·1)
Surgical and medical procedures 0 0 0 (0–0) 1 (0·1%) 1 0 (0–0) 0 0 0 (0–0)
Blood and lymphatic system 
disorders
1 (0·2%) 1 1·6 (0–8·8) 2 (0·3%) 2 2·4 (0·3–8·6) 0 0 0 (0–0)
Nervous system disorders 1 (0·2%) 1 1·6 (0–8·8) 1 (0·1%) 1 1·2 (0–6·7) 0 0 0 (0–0)
Reproductive system and breast 
disorders
1 (0·2%) 1 1·6 (0–8·8) 0 0 0 (0–0) 0 0 0 (0–0)
Respiratory, thoracic, 
and mediastinal disorders
13 (2·5%) 13 20·4 (10·9–34·9) 9 (1·3%) 9 10·7 (4·9–20·4) 10 (1·6%) 10 12·5 (6–23·1)
Metabolism and nutrition disorders 0 0 0 (0–0) 3 (0·4%) 3 3·6 (0·7–10·5) 0 0 0 (0–0)
Hepatobiliary disorders 0 0 0 (0–0) 0 0 0 (0–0) 1 (0·2%) 1 1·3 (0–7)
General disorders and 
administration site conditions
2 (0·4%) 3 4·7 (1–13·8) 2 (0·3%) 2 2·4 (0·3–8·6) 0 0 0 (0–0)
Neoplasms benign, malignant, 
and unspecified (including cysts 
and polyps)
1 (0·2%) 1 1·6 (0–8·8) 0 0 0 (0–0) 0 (0·0%) 0 0 (0–0)
All SAEs were coded using the Medical Dictionary of Regulatory Affairs and are presented here according to their system organ class, the highest level in the dictionary. IPT=intermittent preventive treatment. 
IST=intermittent screening and treatment. SST=single screening and treatment. *Total follow-up was 222·2 years in women and 83·8 years in infants. †Total follow-up was 156·6 years in women and 63·6 years 
in infants. ‡Total follow-up was 187·1 years in women and 79·7 years in infants. §Excluding twin births, including liveborn and stillborn infants.
Table 2: Serious adverse events
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(figures 2–4; appendix pp 17–25). For the primary 
endpoint, the p values of the interaction term depicting 
the difference between sites in the effect of IPT relative to 
IST were p=0·070 (unadjusted) and p=0·015 (adjusted; 
appendix p 17) with adjusted analyses showing no 
significant difference between the two groups in Sumba, 
but a relative risk reduction of 35% (0·65, 0·46-0·91, 
p=0·012, figure 2) in Papua. Similarly, the superior 
effects of IPT relative to IST on malaria infections 
detected in peripheral blood during pregnancy (figure 4), 
and in peripheral blood (appendix p 40) and placental 
blood at delivery (appendix p 43), were also evident only 
in Papua (appendix pp 19–23). The superior effect of IPT 
relative to SST on malaria infections in peripheral blood 
during pregnancy (figure 2) or in placental blood at 
delivery (appendix p 41) was also evident only in 
Papua (appendix pp 21–23). There were no significant 
differences by study site in the effect of IPT versus SST 
or IPT versus IST on the incidence of non-malaria and 
all-cause sick visits (appendix p 23).
The analysis of secondary morbidity outcomes showed 
no significant differences in any anaemia (haemoglobin 
<11 g/dL) or mean maternal haemoglobin levels 
(appendix p 27) between groups when both sites were 
pooled, but in Papua, participants in IPT clusters had a 
lower prevalence of moderate anaemia (haemoglobin 
<9 g/dL) than in SST clusters (figure 2). IPT, but not 
IST, was associated with significantly higher mean 
haemoglobin concentrations in cord blood (p=0·020; 
appendix p 25). Relative to SST, IPT and IST did not 
significantly improve adverse pregnancy outcomes when 
both sites were pooled (figures 2, 3), but in Sumba, the 
risk of adverse pregnancy outcomes was significantly 
higher in the IPT group than in the SST group (figure 2). 
This difference was not apparent in Papua (figure 2; 
appendix p 25).
The main adverse events associated with dihydro-
artemisinin–piperaquine were nausea, headache, and 
vomiting within 7 days after drug intake. In the IPT 
group, nausea occurred after 63 (3%) of 2058 courses, 
headache after 68 (3%) of 2050 courses, and vomiting 
after 87 (4%) of 2058 courses (appendix p 29). There was 
no difference between groups in the number of serious 
adverse events in mothers (table-2). There were three 
maternal deaths, two in the IST group and one in the 
SST group; all were considered unrelated to the 
intervention or malaria (appendix p 30). The prevalence 
of serious adverse events in infants (table-2), and the risk 
of congenital malformations, were very similar between 
groups (appendix pp 47–49).
In total, 33 participants in the IPT group were enrolled 
in the nested cardiac monitoring. Dihydroartemisinin–
piperaquine was associated with a mean QTcF prolongation 
of 20 ms (SD 19·6) and a mean QTcB prolongation of 
14·8 ms (17·6). Neither the mean QTcF nor mean QTcB 
increased with the total number of dihydroartemisinin–
piperaquine courses administered (appendix pp 52–53).
Discussion
This trial highlights that in areas co-endemic for both 
P falciparum and P vivax in Indonesia, IPT with 
dihydroartemisinin–piperaquine compared with the 
predominantly passive detection afforded by the existing 
standard SST strategy resulted in a reduction of 
about 41% in the prevalence of malaria infection at 
delivery, a similar reduction in its incidence during 
pregnancy, and a 78% reduction in the incidence of 
clinical malaria during pregnancy. The effect was evident 
for both P falciparum and P vivax infections (appendix 
p 38), suggesting that monthly dihydroartemisinin–
piperaquine was able to successfully delay P vivax 
relapses in the absence of primaquine, which is 
contraindicated during pregnancy. Of note was the 
marked difference in the efficacy of IPT between the two 
study sites. The beneficial effect was evident only in 
Papua, the higher transmission site, where the prevalence 
at delivery was reduced by 50% and the antenatal malaria 
incidence by 77%, similar to the reductions in similar 
outcomes observed in previous trials with IPT with 
dihydroartemisinin–piperaquine in western Kenya9 and 
Uganda,10 in which the comparator was IPT with 
sulfadoxine–pyrimethamine. The greatest reductions 
were observed for patent parasitaemia (malaria rapid 
diagnostic test or microscopy positive), which was 
91% lower with IPT than with SST at delivery, whereas 
for subpatent infections, the reduction was 40%. Infants 
in the IPT cluster had significantly higher mean 
haemoglobin levels at birth, but otherwise IPT was not 
associated with improvements in birth outcomes.
Compared with SST, the effect of IST was not consistent. 
Although IST was associated with a 44% lower prevalence 
of the primary outcome at delivery, the prevalence 
of malaria was already 55% lower at enrolment. 
Furthermore, the effect was only evident at delivery, with 
no evidence that IST was associated with reductions in 
the incidence of parasitaemia during pregnancy. Few 
participants in the SST and IST groups tested positive on 
malaria rapid diagnostic tests at enrolment or during 
pregnancy, and contrary to expectations, IST did not 
detect more infections than SST, despite the four times 
greater number of screening events. Because the number 
of participants who tested positive for malaria by malaria 
rapid diagnostic tests were similar, a similarly low 
number of participants in the IST and SST groups 
required treatment and thus benefited from the potential 
post-treatment prophylactic effect of piperaquine. The 
observed differences between these two groups in the 
primary outcome at delivery might thus reflect the lower 
transmission intensity in the IST clusters that was evident 
at enrolment or other unknown con founding effects 
rather than a true intervention effect.
Although, there was no difference between IPT and IST 
in the composite primary endpoint overall, analyses that 
adjusted for differences in baseline malaria showed a 
significant difference in treatment effect between Sumba 
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and Papua. There was no significant difference between 
the two groups in Sumba, but a 35% reduction with IPT 
versus IST in the primary outcome in Papua in the 
adjusted analysis. IPT was also more effective than IST in 
reducing malaria infection during pregnancy in Papua. 
The lack of a difference in the effects of IPT versus IST in 
Sumba might reflect the lower transmission intensity 
compared to Papua. It may also reflect the nearly threefold 
difference between the IPT and IST clusters in malaria 
risk that was already evident at enrolment in Sumba.
Approximately 90% of infections were below the limit of 
detection for malaria rapid diagnostic tests. The brand 
used in the trial did well in the WHO product testing of 
malaria rapid diagnostic tests and was the best-performing 
malaria rapid diagnostic test to screen for malaria in 
asymptomatic pregnant women in our previous diagnostic 
study in Sumba;14 although it had an overall sensitivity 
of 32% to detect PCR-positive infections, and only 13% for 
P vivax mono-infections.14 The tests were purchased 
directly from the manufacturer and stored and used 
according to the manufacturer’s instructions.
Dihydroartemisinin–piperaquine was well tolerated, 
with only one participant in the IPT group vomiting 
within 30 min after any dose, an adverse event rate 
that was similar to that reported with sulfadoxine–
pyrimethamine in sub-Saharan Africa.9,10,11 The main 
adverse events were later vomiting, nausea, and headache 
within 3 days after drug intake. Overall, among the 
participants who took dihydroartemisinin–piperaquine, 
almost 90% complied with the 3-day regimen each time 
it was administered. The magnitude of QTc prolongation 
associated with piperaquine was consistent with that 
seen in other studies with a single course of dihydro-
artemisinin–piperaquine and similar to previous trials of 
IPT with dihydroartemisinin–piperaquine in Uganda.9,10 
There was no evidence that QTc prolongation increased 
with subsequent monthly courses, despite the potential 
for dose accumulation of piperaquine when dihydro-
artemisinin–piperaquine is given monthly.27 In Sumba, 
there was a higher number of neonatal deaths in the IST 
clusters than in the other clusters, which was unexplained 
and could have occurred by chance given the deaths were 
not related to dihydroartemisinin–piperaquine use and 
this difference was not observed in Papua. The risk of 
low birthweight was higher in IPT clusters than in SST 
or IST clusters, which was probably a chance finding 
given that this difference was observed only in Sumba.
In a linked feasibility analysis, monthly screening with 
malaria rapid diagnostic tests was found to be well 
accepted by asymptomatic participants and providers.28 By 
contrast, in this current study, the withdrawal rate was 
relatively high in the IPT cluster, particularly in Papua, 
where 14% of participants withdrew, compared with 0% 
and 2% in the IST and SST clusters, respectively. High 
rates of withdrawal from IPT were related to concerns 
about dihydroartemisinin–piperaquine causing potential 
harm to the mother and baby and being a potential 
driver of drug resistance.28 The concept of using 
dihydro artemisinin–piperaquine for chemoprevention in 
asymptomatic individuals is new in this region, where to 
date it has been used only for case management of febrile 
patients with acute malaria. There is an increasing interest 
in use of dihydroartemisinin–piperaquine for chemo-
prevention,9,10,13 as well as for mass drug administration. In 
this context it is imperative that careful consideration be 
given to the optimal use of antimalarials for both treatment 
and prevention, ideally with drugs that generate opposing 
selection pressures on the same target.29 Further feasibility 
studies with dihydro artemisinin–piperaquine as a 
monthly IPT are also warranted before its implementation 
in the region.
The study has several important limitations. First, we 
used a cluster-randomised design, which, owing to the 
modest number of assignment units per arm (26 clinic 
clusters), had a greater potential for bias than trials 
based on randomisation of individuals. The lower 
prevalence of malaria at enrolment in the IST arm 
occurred by chance in both Sumba and Papua, despite 
our attempt to balance the randomisation by malaria 
transmission using locally available annual parasite 
incidence data from the government (appendix p 54). 
The unequal distribution is a potential cause of bias 
because of the strong correlation between malaria 
infection at enrolment and delivery. This is likely to have 
resulted in overestimation of the effect of IST relative to 
SST and underestimation of the effect of IPT relative to 
IST. Second, the study was not powered to detect 
differences in birth outcomes. Furthermore, in Sumba, 
the malaria transmission intensity was lower than in 
previous years, limiting the power to detect differences 
in infection outcomes, especially for patent infections, 
which were detected in only 0·5% of participants at 
enrolment compared with 6·5% in Papua. Patent 
infections are most likely to be associated with adverse 
pregnancy outcomes.3,30–35 Third, only 82% of participants 
contributed to the primary endpoint, which required 
collection of maternal and placental blood within a few 
hours of delivery. Lastly, because HRP2 can remain 
detectable for up to 1 month after parasite clearance in 
patients with clinical malaria, malaria rapid diagnostic 
tests can remain positive for several weeks. This is 
unlikely to have affected our findings as there were no 
cases with a positive malaria rapid diagnostic test and a 
negative qPCR within 1 month.
In conclusion, the effect of IST relative to SST was 
difficult to ascertain as the 44% difference detected at 
delivery was already evident at baseline (55% difference) 
and very few participants tested positive by malaria rapid 
diagnostic test in this setting, where about 90% of infections 
were below the limit of detection. Further studies with 
highly sensitive malaria rapid diagnostic tests should be 
considered. By contrast, our results suggest that in areas in 
the Asia-Pacific region with moderate transmission and 
high-grade sulfadoxine–pyrimethamine and chloroquine 
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resistance, the strategy of monthly IPT with 
dihydroartemisinin–piperaquine could be an effective 
alternative to the existing policy of single screening and 
treatment.
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